Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Spyglass Capital Management LLC

Spyglass Capital Management LLC raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 85.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 262,660 shares of the company's stock after purchasing an additional 120,778 shares during the quarter. Medpace accounts for approximately 4.9% of Spyglass Capital Management LLC's holdings, making the stock its 7th largest holding. Spyglass Capital Management LLC owned 0.85% of Medpace worth $87,264,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Medpace by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock valued at $854,087,000 after acquiring an additional 25,704 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Medpace by 91.8% in the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after acquiring an additional 519,186 shares in the last quarter. Wasatch Advisors LP grew its holdings in shares of Medpace by 3.1% in the 4th quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock valued at $311,247,000 after acquiring an additional 28,161 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Medpace by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock valued at $218,031,000 after acquiring an additional 28,076 shares in the last quarter. Finally, Bessemer Group Inc. grew its holdings in shares of Medpace by 15.0% in the 4th quarter. Bessemer Group Inc. now owns 576,044 shares of the company's stock valued at $191,379,000 after acquiring an additional 75,275 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Trading Up 0.6%

Shares of NASDAQ:MEDP traded up $1.86 during trading on Friday, reaching $294.89. 266,217 shares of the stock were exchanged, compared to its average volume of 353,489. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $459.77. The firm has a market cap of $8.48 billion, a PE ratio of 23.35, a PEG ratio of 3.81 and a beta of 1.55. The stock has a 50-day moving average price of $301.83 and a 200-day moving average price of $326.99.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The company had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. During the same quarter in the previous year, the company posted $3.20 earnings per share. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 20.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MEDP. Leerink Partners began coverage on Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective for the company. William Blair restated a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and decreased their price objective for the company from $370.00 to $328.00 in a report on Monday, April 14th. Robert W. Baird reduced their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Finally, Truist Financial reduced their price target on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday, April 23rd. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.